The Properties of Cytokines in Multiple Sclerosis: Pros and Cons

被引:83
作者
Wang, Kexin [1 ]
Song, Feng [2 ]
Fernandez-Escobar, Alejandro [3 ]
Luo, Gang [4 ]
Wang, Jun-Hui [5 ]
Sun, Yu [6 ]
机构
[1] Shandong Univ, Dept Gen Surg, Qilu Hosp, Jinan, Shandong, Peoples R China
[2] Qingdao Univ, Affiliated Qingdao Municipal Hosp, Qingdao, Shandong, Peoples R China
[3] Univ Toronto, Translat Res Program, Toronto, ON, Canada
[4] Beijing Tiantan Hosp, Dept Intervent Neurol, Beijing, Peoples R China
[5] Univ Toronto, Dept Physiol, Toronto, ON, Canada
[6] Shandong Univ, Dept Endocrinol, Qilu Hosp, Jinan 250012, Shandong, Peoples R China
关键词
Cytokines; Multiple sclerosis; Inflammation; Proinflammatory cytokines; Anti-inflammatory cytokines; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NECROSIS-FACTOR-ALPHA; BRAIN-BARRIER DISRUPTION; GROWTH-FACTOR-BETA; JAK-STAT PATHWAY; QUALITY-OF-LIFE; T-CELLS; IFN-GAMMA;
D O I
10.1016/j.amjms.2018.08.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system and is characterized by demyelination, axonal loss, gliosis and inflammation. The last plays a major role in the onset and propagation of the disease. MS presents with heterogeneous lesions containing a broad range of cells and soluble mediators of the immune system such as T cells, B cells, macrophages, microglia, cytokines, chemokines, antibodies, complement and other toxic substances. This review outlines, analyzes and discusses the different immune mechanisms of MS that are responsible for the initiation and propagation of active lesions, demyelination, axonal injury, remyelination and cell loss as well as the role of cytokines in the disease process. Proinflammatory cytokines such as interleukin-17 (IL-17), IL-22, tumor necrosis factor-alpha, IL-1, IL-12 and interferon-gamma may cause MS through several signaling pathways. Conversely, anti-inflammatory circulating cytokines such as IL-4 and IL-10 are reduced and theoretically can exert a direct protective effect in this condition. Future studies are necessary to develop effective, safe and long-lasting strategies to reduce the abnormal cytokine cascades and to treat MS.
引用
收藏
页码:552 / 560
页数:9
相关论文
共 116 条
[1]   Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice - Models for multiple sclerosis with primary oligodendrogliopathy [J].
Akassoglou, K ;
Bauer, J ;
Kassiotis, G ;
Pasparakis, M ;
Lassmann, H ;
Kollias, G ;
Probert, L .
AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (03) :801-813
[2]   Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? [J].
Antel, Jack ;
Antel, Samson ;
Caramanos, Zografos ;
Arnold, Douglas L. ;
Kuhlmann, Tanja .
ACTA NEUROPATHOLOGICA, 2012, 123 (05) :627-638
[3]   CONTROL OF ESTABLISHED EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS BY INHIBITION OF TUMOR-NECROSIS-FACTOR (TNF) ACTIVITY WITHIN THE CENTRAL-NERVOUS-SYSTEM USING MONOCLONAL-ANTIBODIES AND TNF RECEPTOR IMMUNOGLOBULIN FUSION PROTEINS [J].
BAKER, D ;
BUTLER, D ;
SCALLON, BJ ;
ONEILL, JK ;
TURK, JL ;
FELDMANN, M .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (09) :2040-2048
[4]  
Begolka WS, 1998, RES IMMUNOL, V149, P771
[5]   Health-related quality of life in secondary progressive multiple sclerosis [J].
Beiske, A. G. ;
Naess, H. ;
Aarseth, J. H. ;
Andersen, O. ;
Elovaara, I. ;
Farkkila, M. ;
Hansen, H. J. ;
Mellgren, S. I. ;
Sandberg-Wollheim, M. ;
Sorensen, P. S. ;
Myhr, K. M. .
MULTIPLE SCLEROSIS JOURNAL, 2007, 13 (03) :386-392
[6]  
Bettelli E, 1998, J IMMUNOL, V161, P3299
[7]   IL-22RA2 Associates with Multiple Sclerosis and Macrophage Effector Mechanisms in Experimental Neuroinflammation [J].
Beyeen, Amennai D. ;
Adzemovic, Milena Z. ;
Ockinger, Johan ;
Stridh, Pernilla ;
Becanovic, Kristina ;
Laaksonen, Hannes ;
Lassmann, Hans ;
Harris, Robert A. ;
Hillert, Jan ;
Alfredsson, Lars ;
Celius, Elisabeth G. ;
Harbo, Hanne F. ;
Kockum, Ingrid ;
Jagodic, Maja ;
Olsson, Tomas .
JOURNAL OF IMMUNOLOGY, 2010, 185 (11) :6883-6890
[8]   TNF-mediated inflammatory disease [J].
Bradley, J. R. .
JOURNAL OF PATHOLOGY, 2008, 214 (02) :149-160
[9]  
Bright JJ, 1998, J IMMUNOL, V161, P1772
[10]   Ingested (oral) rituximab inhibits EAE [J].
Brod, Staley A. .
CYTOKINE, 2016, 85 :177-183